Legal & Regulatory

Ionis Gains EU Approval for Tryngolza in Severe Hypertriglyceridemia

IONSIonis Pharmaceuticals, Inc.

Ionis Pharmaceuticals said the European Commission approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia, or sHTG. The approval covers use alongside diet and other lipid-lowering treatments in patients with fasting triglyceride levels of ≥880 mg/dL (≥10 mmol/L).

Ionis announced the decision on 2026-11-17, saying it broadens Tryngolza's availability in Europe. The company said the therapy is the first RNA-targeted medicine cleared in the EU for this adult group, and the only one.

Important questions to consider

It is approved for adult patients with severe hypertriglyceridemia, defined by fasting triglyceride levels of ≥880 mg/dL (≥10 mmol/L). It is to be used alongside diet and other lipid-lowering therapies.

Sources